AR125753A1 - Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos - Google Patents
Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estosInfo
- Publication number
- AR125753A1 AR125753A1 ARP220101162A ARP220101162A AR125753A1 AR 125753 A1 AR125753 A1 AR 125753A1 AR P220101162 A ARP220101162 A AR P220101162A AR P220101162 A ARP220101162 A AR P220101162A AR 125753 A1 AR125753 A1 AR 125753A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibodies
- tigit
- methods
- molecules
- multispecific
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163201537P | 2021-05-04 | 2021-05-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR125753A1 true AR125753A1 (es) | 2023-08-09 |
Family
ID=83933041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220101162A AR125753A1 (es) | 2021-05-04 | 2022-05-03 | Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11718669B2 (https=) |
| EP (1) | EP4333893A4 (https=) |
| JP (1) | JP2024516843A (https=) |
| KR (1) | KR20240006054A (https=) |
| CN (1) | CN117425494A (https=) |
| AR (1) | AR125753A1 (https=) |
| AU (1) | AU2022271331A1 (https=) |
| BR (1) | BR112023022319A2 (https=) |
| CA (1) | CA3217289A1 (https=) |
| CL (1) | CL2023003244A1 (https=) |
| CO (1) | CO2023016037A2 (https=) |
| IL (1) | IL308157A (https=) |
| MX (1) | MX2023013078A (https=) |
| PE (1) | PE20240369A1 (https=) |
| TW (1) | TW202304965A (https=) |
| WO (1) | WO2022236276A2 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR125753A1 (es) | 2021-05-04 | 2023-08-09 | Agenus Inc | Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos |
| WO2025188697A1 (en) * | 2024-03-04 | 2025-09-12 | Agenus Inc. | Methods of treating cancer using anti-cd96/anti-tigit antibodies and combination therapies |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US20040121370A1 (en) | 2002-09-11 | 2004-06-24 | Genentech, Inc. | Novel composition and methods for the treatment of immune related diseases |
| WO2005035575A2 (en) | 2003-08-22 | 2005-04-21 | Medimmune, Inc. | Humanization of antibodies |
| EP3214095B1 (en) | 2005-05-12 | 2019-12-11 | ZymoGenetics, Inc. | Compositions and methods for modulating immune responses |
| WO2007141274A2 (en) | 2006-06-06 | 2007-12-13 | Crucell Holland B.V. | Human binding molecules having killing activity against staphylococci and uses thereof |
| EP3208612B1 (en) | 2008-04-09 | 2019-09-18 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| CA3083324A1 (en) | 2010-03-05 | 2011-09-09 | The Johns Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
| WO2013160396A1 (en) | 2012-04-26 | 2013-10-31 | Boehringer Ingelheim International Gmbh | Combination of cd37 antibodies with bendamustine |
| US9090694B2 (en) * | 2012-04-30 | 2015-07-28 | Janssen Biotech, Inc. | ST2L antibody antagonists |
| MX2014014951A (es) | 2012-06-06 | 2015-03-13 | Oncomed Pharm Inc | Agentes aglutinantes que modulan la trayectoria hippo y sus usos. |
| CN105102480B (zh) | 2012-12-24 | 2019-04-16 | 艾伯维公司 | 催乳素受体结合蛋白及其用途 |
| CA2916681A1 (en) | 2013-07-16 | 2015-01-22 | Genentech, Inc. | Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors |
| PL3036258T3 (pl) | 2013-08-22 | 2023-12-11 | The Council Of The Queensland Institute Of Medical Research | Modulowanie receptora dla leczenia raka i infekcji wirusowych |
| WO2015035112A1 (en) | 2013-09-05 | 2015-03-12 | The Johns Hopkins University | Cancer therapy via a combination of epigenetic modulation and immune modulation |
| CA2922950A1 (en) * | 2013-09-30 | 2015-04-02 | Shinya Ishii | Method for producing antigen-binding molecule using modified helper phage |
| AU2015228372B2 (en) | 2014-03-12 | 2018-05-31 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| WO2015143343A2 (en) | 2014-03-21 | 2015-09-24 | The Brigham And Women's Hospital, Inc. | Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring |
| EP3144388B1 (en) | 2014-05-13 | 2020-07-01 | Chugai Seiyaku Kabushiki Kaisha | T cell-redirecting antigen-binding molecule for cells having immunosuppression function |
| CN105233291A (zh) | 2014-07-09 | 2016-01-13 | 博笛生物科技有限公司 | 用于治疗癌症的联合治疗组合物和联合治疗方法 |
| SG11201700258VA (en) | 2014-07-16 | 2017-02-27 | Genentech Inc | Methods of treating cancer using tigit inhibitors and anti-cancer agents |
| AU2015305754B2 (en) | 2014-08-19 | 2018-10-25 | Merck Sharp & Dohme Llc | Anti-tigit antibodies |
| TWI716362B (zh) | 2014-10-14 | 2021-01-21 | 瑞士商諾華公司 | 針對ｐｄ－ｌ１之抗體分子及其用途 |
| BR112017008399A2 (pt) | 2014-10-24 | 2018-06-19 | StemImmune, Incorporated | abordagem de imunoterapia de combinação para tratamento de câncer |
| KR20170072343A (ko) | 2014-11-06 | 2017-06-26 | 제넨테크, 인크. | Ox40 결합 효능제 및 tigit 억제제를 포함하는 병용 요법 |
| CN107207594B (zh) | 2014-12-23 | 2019-05-07 | 百时美施贵宝公司 | 针对tigit的抗体 |
| WO2016154544A1 (en) | 2015-03-25 | 2016-09-29 | The Regents Of The University Of Michigan | Compositions and methods for delivery of biomacromolecule agents |
| WO2016180781A1 (en) | 2015-05-08 | 2016-11-17 | Michele Maio | Combination therapy of mesothelioma |
| TWI715587B (zh) | 2015-05-28 | 2021-01-11 | 美商安可美德藥物股份有限公司 | Ｔｉｇｉｔ結合劑和彼之用途 |
| AU2016285920A1 (en) | 2015-06-29 | 2018-02-01 | Bristol-Myers Squibb Company | Antibodies to CD40 with enhanced agonist activity |
| EP3328363A4 (en) | 2015-07-31 | 2019-08-21 | Tarveda Therapeutics, Inc. | COMPOSITIONS AND METHOD FOR IMMUNOMODULATION |
| JO3620B1 (ar) | 2015-08-05 | 2020-08-27 | Amgen Res Munich Gmbh | مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم |
| EP3334757A4 (en) | 2015-08-14 | 2019-04-03 | Merck Sharp & Dohme Corp. | ANTI-Tigit ANTIBODY |
| CN114605548A (zh) | 2015-09-01 | 2022-06-10 | 艾吉纳斯公司 | 抗-pd-1抗体及其使用方法 |
| CN108137691B (zh) | 2015-09-02 | 2021-10-19 | 耶路撒冷希伯来大学伊萨姆研究发展有限公司 | 特异性针对人类t-细胞免疫球蛋白和itim结构域(tigit)的抗体 |
| EP3349792A1 (en) | 2015-09-14 | 2018-07-25 | Compass Therapeutics LLC | Compositions and methods for treating cancer via antagonism of the cd155/tigit pathway and tgf- |
| CA2994858C (en) * | 2015-09-25 | 2024-01-23 | Genentech, Inc. | Anti-tigit antibodies and methods of use |
| PL3356413T3 (pl) | 2015-10-01 | 2022-04-19 | Potenza Therapeutics, Inc. | Białka anty-tigit wiążące antygen oraz sposoby ich zastosowania |
| CN108136010A (zh) | 2015-10-08 | 2018-06-08 | 宏观基因有限公司 | 用于治疗癌症的联合疗法 |
| CN114181960B (zh) | 2015-10-09 | 2024-08-23 | 美天施生物科技有限公司 | 嵌合抗原受体和使用方法 |
| EP3402517B1 (en) | 2016-01-15 | 2025-08-20 | RFEMB Holdings, LLC | Immunologic treatment of cancer by using a tumor ablation technic together with a combination of a ctla-4 inhibitor, a pd-1 inhibitor and gm-csf |
| WO2017152088A1 (en) | 2016-03-04 | 2017-09-08 | JN Biosciences, LLC | Antibodies to tigit |
| WO2017218970A1 (en) | 2016-06-17 | 2017-12-21 | Varian Medical Systems, Inc. | Immune modulators in combination with radiation treatment |
| US12257352B2 (en) | 2016-06-20 | 2025-03-25 | The Regents Of The University Of Michigan | Compositions and methods for delivery of biomacromolecule agents |
| CN110088132B (zh) | 2016-08-17 | 2020-10-27 | 康姆普根有限公司 | 抗tigit抗体，抗pvrig抗体及其组合 |
| JP7200093B2 (ja) | 2016-09-15 | 2023-01-06 | アイデラ・ファーマシューティカルズ，インコーポレーテッド | がん治療用ｔｌｒ９アゴニストを用いた免疫調節 |
| CN110662552A (zh) | 2016-11-30 | 2020-01-07 | 昂科梅德制药有限公司 | 包含tigit结合剂的癌症治疗方法 |
| US10759855B2 (en) | 2016-12-02 | 2020-09-01 | Rigel Pharmaceuticals, Inc. | Antigen binding molecules to TIGIT |
| CN109071656B (zh) | 2017-01-05 | 2021-05-18 | 璟尚生物制药公司 | 检查点调节物拮抗剂 |
| EP3589313A4 (en) | 2017-02-28 | 2021-05-19 | Seagen Inc. | ANTI-TIGITE ANTIBODY |
| JOP20190203A1 (ar) | 2017-03-30 | 2019-09-03 | Potenza Therapeutics Inc | بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها |
| RS64576B1 (sr) | 2017-05-01 | 2023-10-31 | Agenus Inc | Anti-tigit antitela i postupci njihove primene |
| JP7402693B2 (ja) | 2017-05-02 | 2023-12-21 | メルク・シャープ・アンド・ドーム・エルエルシー | 単独のおよびプログラム死受容体１（ｐｄ－１）抗体と組み合わされた抗ｔｉｇｉｔ抗体の安定な製剤、ならびにその使用方法 |
| WO2018229163A1 (en) | 2017-06-14 | 2018-12-20 | King's College London | Methods of activating v delta 2 negative gamma delta t cells |
| GB201709808D0 (en) | 2017-06-20 | 2017-08-02 | Kymab Ltd | Antibodies |
| IL272227B2 (en) | 2017-07-27 | 2025-09-01 | iTeos Belgium SA | Anti-tigit antibodies |
| CN111655286A (zh) | 2017-08-11 | 2020-09-11 | 布林克生物医学简易股份公司 | 作为免疫调节剂的cd96结合剂 |
| US11512129B2 (en) | 2017-09-29 | 2022-11-29 | Jiangsu Hengrui Medicine Co., Ltd. | TIGIT antibody, antigen-binding fragment thereof, and medical use thereof |
| WO2019091449A1 (zh) | 2017-11-10 | 2019-05-16 | 江苏恒瑞医药股份有限公司 | Cd96抗体、其抗原结合片段及医药用途 |
| TW201930358A (zh) | 2017-12-28 | 2019-08-01 | 大陸商南京傳奇生物科技有限公司 | 針對ｔｉｇｉｔ之單域抗體及其變異體 |
| TWI816729B (zh) * | 2017-12-30 | 2023-10-01 | 英屬開曼群島商百濟神州有限公司 | 抗tigit抗體及其作為治療和診斷的用途 |
| KR20200109313A (ko) | 2018-01-15 | 2020-09-22 | 난징 레전드 바이오테크 씨오., 엘티디. | Tigit에 대한 항체 및 이의 변이체 |
| WO2019152574A1 (en) | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Methods for treating cancer or infection using a combination of an anti-pd-1 antibody, an anti-lag3 antibody, and an anti-tigit antibody |
| CA3086936C (en) | 2018-02-06 | 2022-11-29 | I-Mab Biopharma Us Limited | Antibodies to t cell immunoreceptor with ig and itim domains (tigit) and uses thereof |
| CN111836831A (zh) | 2018-02-26 | 2020-10-27 | 豪夫迈·罗氏有限公司 | 用于抗tigit拮抗剂抗体和抗pd-l1拮抗剂抗体治疗的给药 |
| MX2020008795A (es) | 2018-02-28 | 2020-10-08 | Yuhan Corp | Anti cuerpos anti tigit y usos de los mismos. |
| JP2021534196A (ja) | 2018-08-23 | 2021-12-09 | シージェン インコーポレイテッド | 抗ｔｉｇｉｔ抗体 |
| EA202191176A1 (ru) * | 2018-10-31 | 2021-07-28 | Делиниа, Инк. | Поливалентные модуляторы регуляторных т-клеток |
| AR117327A1 (es) * | 2018-12-20 | 2021-07-28 | 23Andme Inc | Anticuerpos anti-cd96 y métodos de uso de estos |
| EP3938396A1 (en) * | 2019-03-11 | 2022-01-19 | Jounce Therapeutics, Inc. | Anti-icos antibodies for the treatment of cancer |
| TWI760751B (zh) | 2019-05-29 | 2022-04-11 | 美商美國禮來大藥廠 | Tigit及pd-1/tigit-結合分子 |
| CA3285695A1 (en) * | 2019-06-26 | 2026-03-02 | Ap Biosciences, Inc. | Antibodies for t-cell activation |
| TW202122420A (zh) | 2019-08-30 | 2021-06-16 | 美商艾吉納斯公司 | 抗ｃｄ９６抗體及其使用方法 |
| AR125753A1 (es) | 2021-05-04 | 2023-08-09 | Agenus Inc | Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos |
| CN117241827A (zh) * | 2021-05-04 | 2023-12-15 | 艾吉纳斯公司 | 抗tigit抗体及其使用方法 |
-
2022
- 2022-05-03 AR ARP220101162A patent/AR125753A1/es not_active Application Discontinuation
- 2022-05-03 TW TW111116719A patent/TW202304965A/zh unknown
- 2022-05-04 WO PCT/US2022/072099 patent/WO2022236276A2/en not_active Ceased
- 2022-05-04 JP JP2023568081A patent/JP2024516843A/ja active Pending
- 2022-05-04 MX MX2023013078A patent/MX2023013078A/es unknown
- 2022-05-04 CN CN202280040311.3A patent/CN117425494A/zh active Pending
- 2022-05-04 KR KR1020237041635A patent/KR20240006054A/ko active Pending
- 2022-05-04 PE PE2023003002A patent/PE20240369A1/es unknown
- 2022-05-04 AU AU2022271331A patent/AU2022271331A1/en active Pending
- 2022-05-04 CA CA3217289A patent/CA3217289A1/en active Pending
- 2022-05-04 IL IL308157A patent/IL308157A/en unknown
- 2022-05-04 EP EP22799792.1A patent/EP4333893A4/en active Pending
- 2022-05-04 BR BR112023022319A patent/BR112023022319A2/pt unknown
- 2022-08-10 US US17/818,840 patent/US11718669B2/en active Active
-
2023
- 2023-06-13 US US18/333,882 patent/US12479913B2/en active Active
- 2023-11-02 CL CL2023003244A patent/CL2023003244A1/es unknown
- 2023-11-23 CO CONC2023/0016037A patent/CO2023016037A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022271331A1 (en) | 2023-10-26 |
| EP4333893A2 (en) | 2024-03-13 |
| BR112023022319A2 (pt) | 2024-02-20 |
| CA3217289A1 (en) | 2022-11-10 |
| CO2023016037A2 (es) | 2023-11-30 |
| MX2023013078A (es) | 2023-11-16 |
| US12479913B2 (en) | 2025-11-25 |
| WO2022236276A2 (en) | 2022-11-10 |
| US20230014036A1 (en) | 2023-01-19 |
| JP2024516843A (ja) | 2024-04-17 |
| TW202304965A (zh) | 2023-02-01 |
| US20240141039A1 (en) | 2024-05-02 |
| CN117425494A (zh) | 2024-01-19 |
| EP4333893A4 (en) | 2025-06-18 |
| AU2022271331A9 (en) | 2023-11-09 |
| WO2022236276A3 (en) | 2023-01-19 |
| IL308157A (en) | 2024-01-01 |
| PE20240369A1 (es) | 2024-03-04 |
| CL2023003244A1 (es) | 2024-04-19 |
| US11718669B2 (en) | 2023-08-08 |
| KR20240006054A (ko) | 2024-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024009690A (es) | Anticuerpos anti-cd137 y metodos de uso de los mismos. | |
| BR112022014667A2 (pt) | Anticorpos de domínio único de cd28 e construtos multivalentes e multiespecíficos dos mesmos | |
| CY1123932T1 (el) | Δομες πολυειδικου αντισωματος | |
| MX2020009394A (es) | Anticuerpos anti-cd73 y métodos de uso de los mismos. | |
| CO2019001367A2 (es) | Proteínas de unión de tipo anticuerpo biespecíficas que se unen específicamente a cd3 y cd123 | |
| CO2018012415A2 (es) | Proteínas de unión específica y usos de las mismas | |
| MX2020009514A (es) | Anticuerpos anti-claudina 18.2 (cldn18.2). | |
| AR115389A1 (es) | Anticuerpo antagonista de cd73 | |
| ECSP22014455A (es) | Anticuerpos anti-cd96 y sus métodos de uso | |
| BR112019007369A2 (pt) | anticorpos anti-lag-3 e métodos de uso dos mesmos | |
| MX2019006340A (es) | Anticuerpos anti antígeno 4 del linfocito t citotóxico (ctla-4) y métodos de uso de los mismos. | |
| BR112018074463A2 (pt) | anticorpos anti-tim-3 e métodos de uso dos mesmos. | |
| BR112017010110A2 (pt) | anticorpos contra cd73 e usos do mesmo | |
| CL2016000438A1 (es) | Anticuerpos humanizados que se unen específicamente al receptor del factor estimulante de colonias 1 (csf-1r); ácidos nucleicos; vectores de expresión, células huéspedes; procesos de producción; composiciones farmacéuticas; usos y métodos de tratamiento terapéutico para el tratamiento del cáncer y de la enfermedad fibrótica | |
| BR112019003866A2 (pt) | adenovírus estimulado com fragmento de mab biespecífico com redirecionamento de células t (bite) | |
| BR112022011854A2 (pt) | Anticorpos, polinucleotídeo isolado, célula hospedeira, métodos para produzir um anticorpo e para tratar uma doença, composição farmacêutica, usos do anticorpo e invenção | |
| DOP2015000110A (es) | Anticuerpos anti-ceacam5 y usos de estos | |
| BR112022004047A2 (pt) | Proteínas de ligação multiespecíficas para o tratamento de câncer | |
| BR112017007093A2 (pt) | composições e métodos de uso para aumento da resposta imune e terapia do câncer | |
| BR112015017548A8 (pt) | construção de anticorpo multiespecífico isolado, sequência de ácido nucléico, vetor, célula hospedeira, processo para a produção da construção de anticorpo, composição farmaceutica, uso da construção de anticorpo e kit | |
| BR112019005316A2 (pt) | anticorpos monoclonais para morte programada 1 (pd-1) | |
| CO2023016037A2 (es) | Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos | |
| CL2020001137A1 (es) | Anticuerpos anti-apoc3 y métodos de uso de estos. | |
| MX2020012649A (es) | Neoantígenos especificos de tumor y métodos de uso de estos. | |
| MX2021006489A (es) | Compuestos heteroaromaticos como inhibidores de vanina. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |